Gilead Appoints EVP, Oncology TherapeuticsBy
Gilead Sciences has promoted Alessandro Riva, MD, to executive vice president, Oncology Therapeutics, with responsibility for Gilead’s hematology and oncology programs, including cell-therapy research and development. Riva will become a member of Gilead’s senior leadership team.
Riva joined Gilead in January 2017 as senior vice president, hematology, and Oncology Therapeutic Area Head. He aided in expanding Gilead’s oncology program to include cell therapy with Gilead’s recent acquisition of Kite Pharma. He also guided the strategy and development of Gilead’s broader oncology pipeline during his tenure.
Prior to joining Gilead, Riva served as head, Global Oncology Development at Novartis, where he oversaw the development and worldwide regulatory approval of multiple compounds in a variety of tumor types.
Source: Gilead Sciences